PFE
Latest Trade
38.33USDChange
-0.15(-0.39%)Volume
11,561,154Today's Range
-
38.6652 Week Range
-
40.97As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 38.48 |
|---|---|
Open | 38.61 |
Volume | 11,561,154 |
3M AVG Volume | 660.07 |
Today's High | 38.66 |
Today's Low | 38.22 |
52 Week High | 40.97 |
52 Week Low | 27.88 |
Shares Out (MIL) | 5,554.83 |
Market Cap (MIL) | 213,750.00 |
Forward P/E | 13.33 |
Dividend (Yield %) | 3.95 |
Kymera Therapeutics Inc Files For IPO Of Up To $100 Million - SEC Filing
Pfizer Reports Q2 Adjusted Earnings Per Share $0.78
Biontech Announces Proposed Public Offerings
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Industry
Biotechnology & Drugs
Executive Leadership
Albert Bourla
Chairman of the Board, Chief Executive Officer
John D. Young
Chief Business Officer, Group President
Frank A. D'Amelio
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Angela Hwang
Group President, Pfizer Biopharmaceuticals Group
Dawn Rogers
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM) | 14.06 |
|---|---|
Price To Sales (TTM) | 4.22 |
Price To Book (MRQ) | 3.29 |
Price To Cash Flow (TTM) | 10.09 |
Total Debt To Equity (MRQ) | 80.41 |
LT Debt To Equity (MRQ) | 55.79 |
Return on Investment (TTM) | 12.02 |
Return on Equity (TTM) | 9.63 |
Pfizer Inc <PFE.N> and BioNTech SE <BNTX.O> have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said on Friday.
Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their mRNA-based vaccine candidate against the novel coronavirus in the first half of 2021, the companies said on Friday.
Pfizer Inc <PFE.N> on Tuesday said other developed countries would not get a lower price for its coronavirus vaccine than what it will charge the United States under a contract announced last week, and suggested that people may need multiple vaccinations in order to remain...
Drugmaker Pfizer Inc <PFE.N> is in concurrent talks with the European Union as well as several of its member states to sell them the COVID-19 vaccine candidate it is developing, Chief Executive Albert Bourla said in an interview on Tuesday.
Drugmaker Pfizer Inc is in concurrent talks with the European Union as well as several of its member states to sell them the COVID-19 vaccine candidate it is developing, Chief Executive Albert Bourla said in an interview on Tuesday.
Pfizer Inc reported a 32% fall in second-quarter profit on Tuesday due to a dip in demand for some of its drugs from the COVID-19 pandemic and from rising competition, as the company and partner began a global study into a vaccine candidate to fight the health crisis.
Pfizer Inc <PFE.N> Chief Executive Albert Bourla said the drugmaker could rethink plans to expand in the United States if the country implements an executive order signed by President Donald Trump last week that would tie the prices Medicare patients pay for drugs to those...
Pfizer Inc Chief Executive Albert Bourla said the drugmaker could rethink plans to expand in the United States if the country implements an executive order signed by President Donald Trump last week that would tie the prices Medicare patients pay for drugs to those paid...
Moderna Inc <MRNA.O> and Pfizer Inc <PFE.N> launched two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year, the companies said on Monday.
German biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.
German biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a global study to evaluate their lead COVID-19 vaccine candidate.
European efforts to secure potential COVID-19 vaccines from Pfizer <PFE.N>, Sanofi <SASY.PA> and Johnson & Johnson <JNJ.N> are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.
Brazil is looking into acquiring doses of a potential coronavirus vaccine under development by Pfizer Inc, which will be tested in the country, Interim Health Minister Eduardo Pazuello said on Wednesday.
Corona Capital is a daily column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.
The U.S. government will pay nearly $2 billion to buy enough of a COVID-19 vaccine being developed by Pfizer Inc <PFE.N> and German biotech BioNTech SE <22UAy.F> to innoculate 50 million people if it proves to be safe and effective, the companies said on Wednesday.
U.S. Health and Human Services Secretary Alex Azar said on Wednesday the federal government has signed a contract with Pfizer Inc. <PFE.N> for 100 million doses of coronavirus vaccine, once it is approved.
U.S. Health and Human Services Secretary Alex Azar said on Wednesday the federal government has signed a contract with Pfizer Inc for 100 million doses of coronavirus vaccine, once it is approved.
Moderna Inc and Merck & Co on Tuesday told a U.S. Congressional panel that they expect to profit from their coronavirus vaccines once approved, amid concerns the vaccines may not be accessible to all.
German biotech BioNTech and U.S. drugmaker Pfizer Inc on Monday said data from an early-stage trial of their experimental coronavirus vaccine showed that it prompted an immune response and was well-tolerated, similar to results seen in prior early test.
Britain has signed deals to secure 90 million doses of two possible COVID-19 vaccines from an alliance of Pfizer Inc <PFE.N> and BioNTech <22UAy.F>, and French group Valneva <VLS.PA>, the business ministry said on Monday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.